Skip to main content

LAVA Therapeutics宣布首次公开发行股价

Written by Customer Service on . Posted in Public Companies.

荷兰乌得勒支和美国费城, March 25, 2021 (GLOBE NEWSWIRE) — LAVA Therapeutics B.V.（纳斯达克股票代码：LVTX），一家专注于使用其在双特异性gamma-delta T细胞衔接蛋白抗体构建体方面的专业知识来转变癌症疗法的生物科技公司，今天宣布其首次公开发行的6,7000,000股普通股定价为每股15美元。此外，LAVA Therapeutics还授予承销商30天的期权，以首次公开发行价格减去承销折扣和佣金的价格额外购买至多1,005,000股普通股。所有股票都由LAVA提供。该支股票预计将于2021年3月25日在纳斯达克全球精选市场开始交易，股票代码为“LVTX”。

在扣除LAVA应支付的承销折扣、佣金和其他优惠费用之前，预计该股票的总收益为1.005亿美元。股票发行预计将于2021年3月29日结束，但须满足传统成交条件。

J.P.MORGAN、Jefferies和SVB Leerink担任本次发行的联合账簿管理人。Kempen & Co担任本次发行的主承销商。

这些证券有关的登记声明已于2021年3月24日生效。本次募股仅通过招股说明书进行，副本可向以下部门索取：J.P. Morgan Securities LLC，个人到访：c/o Broadridge Financial Solutions，地址：1155 Long Island Avenue, Edgewood, NY 11717，或通过电话：(866) 803-9204，或通过电子邮件： prospectus_eqfi@jpmchase.com；Jefferies LLC，个人到访：Equity Syndicate Prospectus Department，地址：520 Madison Avenue, 2nd Floor, New York, NY 10022，或通过电话：(877) 821-7388，或通过电子邮件： prospectus_department@Jefferies.com；SVB Leerink LLC，个人到访：Syndicate Department，地址：One Federal Street, 37th Floor, Boston, MA 02110，或通过电话：(800) 808-7525, ext. 6105，或通过电子邮件：syndicate@svbleerink.com。

本新闻稿不构成出售或招揽购买要约，如有任何州或司法管辖区的证券法规定在进行登记或取得资格之前的要约、招揽或出售属于非法，则不得在该州或司法管辖区对该证券进行任何出售。

前瞻性声明

本新闻稿包含某些含“前瞻性声明”的披露内容，包括但不限于关于LAVA对其在纳斯达克全球精选市场的股票交易预期的声明，以及结束和完成发行的时间。前瞻性声明基于LAVA当前的预期，并受到难以预测的固有不确定性、风险和假设的影响。可能导致实际结果有所不同的因素包括但不限于与满足传统成交条件和完成报价有关的风险和不确定性。这些以及其他风险和不确定性在与将提交给证券交易委员会的交易相关的最终招股说明书中题为“风险因素”的章节中有更全面的描述。本新闻稿中包含的前瞻性声明于此日期做出，除适用法律要求的情况外，LAVA无义务更新此类信息。

公司联系方式：

IR@lavatherapeutics.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.